Pharvaris Netherlands B.V. clinical trial pipeline

2 trials changed in the last 30 days: 0 stopped, 2 with notable changes, 0 with minor changes only.

1. Notable

   CHAPTER-4 · Oral Deucrictibant Extended-Release Tablet for…CHAPTER-4 · Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and · HAE

   Primary endpoint(s) modified

   Also in this update: Trial status changed: Recruiting → Enrolling by Invitation

   Pharvaris Netherlands B.V.·Phase 3· NCT06679881· Registry history of NCT06679881 on ClinicalTrials.gov (opens the registry)

   Updated Sep 22, 2026

2. Notable

   CREAATE · Oral Deucrictibant XR Tablet for Prophylaxis and…CREAATE · Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks · Acquired Angioedema Due to C1 Inhibitor Deficiency

   Primary endpoint(s) modified

   Also in this update: Enrollment increased: 32 → 48 participants

   Pharvaris Netherlands B.V.·Phase 3· NCT07266805· Registry history of NCT07266805 on ClinicalTrials.gov (opens the registry)

   Updated Sep 21, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.